PTD-mediated delivery of anti-cell death proteins/peptides and therapeutic enzymes

Adv Drug Deliv Rev. 2008 Mar 1;60(4-5):499-516. doi: 10.1016/j.addr.2007.09.011. Epub 2007 Nov 13.

Abstract

Millions of unnecessary cells are removed from our body everyday by apoptosis to ensure our survivals. Apoptosis is a highly coordinated process. Failure in apoptotic regulation results in disease. A large number of studies have demonstrated that accelerated apoptosis is involved in degenerative diseases, ischemic injuries, immunodeficiency and infertility. These studies have also revealed the molecular mechanisms of apoptosis signal transduction to provide therapeutic targets. On the other hand, protein transduction technology has been developed to deliver full-length proteins to various tissues including the brain. So far, many studies have shown that in vivo delivery of therapeutic proteins/peptides, including anti-apoptotic proteins, an anti-oxidant enzyme, a neuroprotectant, enzymes involved in purine or tyrosine metabolism, caspase inhibitors, c-Jun N-terminal kinase inhibitors and an NF-kappaB inhibitor, by protein transduction technology mitigates various diseases in animal models.

Publication types

  • Review

MeSH terms

  • Animals
  • Carrier Proteins / chemistry
  • Cell Survival / drug effects
  • Drug Delivery Systems / methods*
  • Enzyme Therapy
  • Enzymes / administration & dosage
  • Enzymes / chemistry
  • Humans
  • Models, Theoretical
  • Peptides / chemistry*
  • Protein Transport
  • Proteins / administration & dosage*
  • Proteins / chemistry
  • Proteins / therapeutic use

Substances

  • Carrier Proteins
  • Enzymes
  • Peptides
  • Proteins